ZILA Zila (MM)

Zila, Inc. (Nasdaq GM: ZILA) filed a Preliminary Proxy Statement after market on August 22, 2006 in preparation for a Special Shareholders Meeting to be convened for the purpose of approving the divestiture of its nutraceutical subsidiary, Zila Nutraceuticals, Inc. For further information, visit www.sec.gov. About Zila Zila, Inc., headquartered in Phoenix, is a leading cancer diagnostic company initially focused on oral cancer: -- Zila Pharmaceuticals is dedicated to establishing ViziLite(R) Plus as the new standard of care within dental offices nationally for the early detection of oral abnormalities that could lead to cancer. -- Zila Biotechnology is focused on achieving regulatory approval for the next generation oral cancer diagnostic, OraTest(R), followed by the development of additional applications of its cancer detection technologies including products for the early detection of cervical and esophageal cancer. For more information about Zila, visit www.zila.com.